A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.
Evotec signs an agreement with Hypha Discovery to provide its screening clients with access to Hypha’s MycoDiverse natural product collection for use as part of its hit and lead identification services.
Just like the rest of us, scientists today are swamped with information. As more chemical resources become freely available, text mining applications - previously focused on correctly identifying gene and protein names – are now shifting towards also correctly identifying chemical names.
Thermo Fisher Scientific Inc. launches the Evolution Array, a new UV-Visible (UV-Vis) spectrophotometer driven by photodiode array (PDA) technology that offers dramatic improvements in laboratory throughput.
Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, has added 2,200 new Prestige Antibodies powered by Atlas Antibodies to its industry-leading portfolio.
Merck & Co., Inc. announced that Roger J. Pomerantz, M.D., has been named senior vice president of Merck Research Laboratories (MRL) and Infectious Diseases Franchise Head.
Researchers at The University of Edinburgh have developed tiny chemical sensors comprose of gold-coated particles that could help diagnose disease and track its progress.
Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria’s survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein’s activity.
Merck KGaA announced that Erbitux (cetuximab) can now be used in Japan in combination with chemotherapy in the first-line-treatment for patients with epidermal growth factor receptor (EGFR)-expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer (mCRC) carrying the KRAS wildtype gene.
A Phase 2 clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.
Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Celerion, a privately owned contract research organization, has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services.
The factors instrumental in triggering latent tuberculosis (TB) infection to progress into active disease have long remained elusive to researchers.
Pathogenic bacteria in the gut recognise their surroundings by detecting hormone signals from the host, which can prompt them to express lethal toxins.